Nursing Perspectives on the Impact of Immune Checkpoint Inhibitors in Early Stages of Cancer

Learn more about the role of immune checkpoint inhibitors in early stages of cancer and gain expert insight on optimal strategies to prevent, mitigate, and manage immune-related adverse events associated with the use of immune checkpoint inhibitors with an on-demand webcast, downloadable slides from a live webinar, and a downloadable patient communication checklist.

Share

Program Content

Activities

Nursing Perspectives on ICIs
Nursing Perspectives on the Impact of Immune Checkpoint Inhibitors in Early Stages of Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 08, 2023

Activities

ICIs for Early Cancer
Nursing Perspectives on the Impact of Immune Checkpoint Inhibitors in Early Stages of Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2023

Expires: July 16, 2024

Activities

ICIs: Patient Communication Guide
Immune Checkpoint Inhibitors in Early Stages of Cancer: A Guide for Counseling Patients
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: May 08, 2023

Faculty

cover img faculity

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature
Oncology Service Line
Yale New Haven Health
Oncology Nurse Practitioner- Senior APP II
Smilow Cancer Hospital, Yale-New Haven
Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

cover img faculity

Ronan J. Kelly, MD, MBA

Director, Charles A. Sammons
Cancer Center                           
W.W. Caruth Jr. Endowed Chair
of Immunology                              
Baylor University Medical Center
Chief, Oncology Baylor Scott & White Health System (NTx)   
Clinical Professor                       
Texas A&M University
College of Medicine                                  
Dallas, Texas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb